Martin Duvall

Martin Duvall

Vorsitzender bei
Oncopeptides, Inc.
64 Jahre
Health Technology
Consumer Services
Health Services

Profil

Martin J.
Duvall
is currently Chairman at Oncopeptides, Inc., Director at Oncopeptides Incentive AB, and Senior Vice President-Commercial Operations at MGI PHARMA Biologics, Inc. Former roles include Chief Executive Officer & Director at Tocagen, Inc. (2016–2020), Chief Executive Officer at Oncopeptides AB (2020–2021), Senior Vice President & General Manager at Merck & Co., Inc. (2010–2011), Senior Vice President-Commercial Operations at MGI PHARMA, Inc. (2004–2011), Chief Commercial Officer & Executive VP at ARIAD Pharmaceuticals, Inc. (2015–2016), Senior Vice President-Global Marketing at Abraxis BioScience, Inc. (2009–2011), and Vice President at Aventis Pharmaceuticals, Inc. Education includes graduate studies at The Johns Hopkins University, undergraduate studies at Muhlenberg College, and an MBA from the University of Kansas.

Aktive Positionen von Martin Duvall

UnternehmenPositionBeginn
Corporate Officer/Principal 01.11.2004
Vorsitzender -
Oncopeptides Incentive AB
Direktor/Vorstandsmitglied -

Ehemalige bekannte Positionen von Martin Duvall

UnternehmenPositionEnde
ONCOPEPTIDES AB Vorstandsvorsitzender 15.11.2021
FORTE BIOSCIENCES, INC. Vorstandsvorsitzender 15.06.2020
ARIAD PHARMACEUTICALS, INC. Corporate Officer/Principal 26.05.2016
MERCK & CO., INC. Corporate Officer/Principal 01.09.2011
Corporate Officer/Principal 27.04.2011
Sehen Sie sich die Erfahrung von Martin Duvall im Detail an

Ausbildung von Martin Duvall

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Beziehungen

67

Beziehungen ersten Grades

13

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Unternehmensverbindungen

Private Unternehmen13

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Consumer Services

Health Technology

Health Technology

Oncopeptides Incentive AB

Health Services

  1. Börse
  2. Insiders
  3. Martin Duvall